Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.

doi:10.1056/NEJMoa1716078

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.

The New England journal of medicine - 24 May 2018

Forde Patrick M, Chaft Jamie E, Smith Kellie N, Anagnostou Valsamo, Cottrell Tricia R, Hellmann Matthew D, Zahurak Marianna, Yang Stephen C, Jones David R, Broderick Stephen, Battafarano Richard J, Velez Moises J, Rekhtman Natasha, Olah Zachary, Naidoo Jarushka, Marrone Kristen A, Verde Franco, Guo Haidan, Zhang Jiajia, Caushi Justina X, Chan Hok Yee, Sidhom John-William, Scharpf Robert B, White James, Gabrielson Edward, Wang Hao, Rosner Gary L, Rusch Valerie, Wolchok Jedd D, Merghoub Taha, Taube Janis M, Velculescu Victor E, Topalian Suzanne L, Brahmer Julie R, Pardoll Drew M

Abstract excerpt

BACKGROUND: Antibodies that block programmed death 1 (PD-1) protein improve survival in patients with advanced non-small-cell lung cancer (NSCLC) but have not been tested in resectable NSCLC, a condition in which little progress has been made during the past decade. METHODS: In this pilot study, we administered two preoperative doses of PD-1 inhibitor nivolumab in adults with untreated, surgically resectable...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antibodies, Monoclonal

Share to B7-H1 Antigen

Share to Biopsy

Share to Carcinoma, Squamous Cell

Share to Neoadjuvant Therapy

Share to Nivolumab

Share to Pilot Projects

Source

Open in PubMed Open full text

Identifiers

PMID: 29658848
DOI: 10.1056/NEJMoa1716078
PMCID: PMC6223617

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.PMID 29658848Read ↗

Neoadjuvant Chemoimmunotherapy in Patients with Resectable Non-small Cell Lung Cancer.Semantic proximity Read ↗

PD-L1 expression and Tumor mutation burden as Pathological response biomarkers of Neoadjuvant immunotherapy for Early-stage Non-small cell lung cancer: A systematic review and meta-analysis.Semantic proximity Read ↗

Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with stages IB-select IIIB resectable non-small cell lung cancer.Semantic proximity Read ↗

The impact of oncogenic driver mutations on neoadjuvant immunotherapy outcomes in patients with resectable non-small cell lung cancer.Semantic proximity Read ↗

Neoadjuvant PD-(L)1 blockade plus platinum-based chemotherapy for potentially resectable oncogene-positive non-small cell lung cancer.Semantic proximity Read ↗

Current indications for surgery in patients with lung cancer after neoadjuvant targeted therapy: a systematic review.Semantic proximity Read ↗

Neoadjuvant immunochemotherapy vs. neoadjuvant targeted therapy plus chemotherapy for EGFR-mutated non-small cell lung cancer: a retrospective study.Semantic proximity Read ↗

PD-1 Blockade-activated Neoantigen Specific Cellular Therapy For Advanced Relapsed Non Small Cell Lung CancerSemantic proximity Read ↗

Predicting therapeutic response to neoadjuvant immunotherapy based on an integration model in resectable stage IIIA (N2) non-small cell lung cancer.Semantic proximity Read ↗

The Evolving Role for Systemic Therapy in Resectable Non-small Cell Lung Cancer.Semantic proximity Read ↗

Systemic neoantigen-specific T cells reveal central determinants of PD-(L)1 blockade efficacySemantic proximity Read ↗

A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.